Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CRN01941 Oral Solution
CRN01941 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single Ascending Dose (Part 1) | EXPERIMENTAL | - |
| Multiple Ascending Dose (Part 2) | EXPERIMENTAL | - |
| Elderly Cohort (Part 3) | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| CRN01941 Oral Solution | DRUG | Investigational drug |
| CRN01941 Oral Capsule | DRUG | Investigational drug |
| Placebo Oral Solution | DRUG | Placebo |
| Placebo Oral Capsule | DRUG | Placebo |
Inclusion Criteria: 1. Male and female subjects 18 to 55 years of age, inclusive, at time of screening (Parts 1 and 2 only). 2. Males and females subjects 65 to 85 years of age at screening (Part 3 only). 3. Females must be non-pregnant and non-lactating, postmenopausal by history and confirmed by ...
CRN01941 is an investigational small molecule developed by Crinetics Pharmaceuticals, Inc. It has been studied in a Phase 1 clinical trial in healthy adult volunteers. The specific therapeutic indications for CRN01941 have not been disclosed.
CRN01941 targets the somatostatin receptor type 2 (SST2), a G protein-coupled receptor. By binding to SST2, CRN01941 acts as a receptor agonist, modulating signaling pathways associated with somatostatin. This mechanism is being explored in early-stage clinical development.
CRN01941 is being developed by Crinetics Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol CRNX. The company focuses on the discovery and development of small molecule therapeutics targeting endocrine and metabolic disorders.
CRN01941 is in Phase 1 clinical development. A single and multiple-ascending dose study has been completed. The drug is investigational and has not been approved by the FDA or any other regulatory agency for any indication.
CRN01941 has been evaluated in one completed Phase 1 trial, NCT03936166, titled "A Single and Multiple-Ascending Dose Study of CRN01941 in Healthy Adult Volunteers." The trial enrolled 57 healthy participants in Australia and was randomized, double-blind, and placebo-controlled.
Yes, CRN01941 Oral Solution is an alternative name for CRN01941. Both refer to the same investigational small molecule developed by Crinetics Pharmaceuticals. The oral solution formulation was used in the Phase 1 clinical trial.